Skip to content
lifestyle.hungrybear.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
City Therapeutics
Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting
November 4, 2026
City Therapeutics to Present at Upcoming November Investor Conferences
November 3, 2026
City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 19, 2026
City Therapeutics Announces Pricing of Upsized Initial Public Offering
October 15, 2026